Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Apremilast Therapy for Acute Gouty Arthritis

This study has been withdrawn prior to enrollment.
(Colaborator withdrew support.)
Sponsor:
Collaborator:
Celgene Corporation
Information provided by:
Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier:
NCT00997581
First received: October 9, 2009
Last updated: July 5, 2011
Last verified: July 2011
  Purpose

The purpose of the study is to learn about a possible new medicine, apremilast, for treating acute gout and compare how it works to indomethacin, a medication that has been used to treat gout for over 50 years.

In order to learn about apremilast, half the participants in this study will receive apremilast and half the participants in this study will receive indomethacin.

This study will measure the severity and duration of acute gout attacks in research participants, as well as measures of quality of life and any side effects or adverse reactions to the medication.

There will be three study visits: a screening/baseline visit on Day 1, a visit to evaluate response to treatment with study medication at Day 7, and a follow-up visit at Day 21.


Condition Intervention Phase
Acute Gout
Drug: apremilast
Drug: indomethacin SR
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: Apremilast Therapy for Acute Gouty Arthritis

Resource links provided by NLM:


Further study details as provided by Dartmouth-Hitchcock Medical Center:

Primary Outcome Measures:
  • Subject-reported number of swollen joints, the number of tender joints, the number of warm joints, as well as self-report pain, global assessment, and functional status. Subject-reported time to resolution of symptoms will be measured. [ Time Frame: Day 1, Day 7 and Day 21. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety (type, frequency, severity, and relationship of adverse events to apremilast, laboratory, ECG, physical exam or other changes) and tolerability [ Time Frame: Day 1, Day 7 and Day 21. ] [ Designated as safety issue: Yes ]
  • Quality of Life [ Time Frame: Assessed at Day 1, Day 7 and Day 21 study visits ] [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: April 2010
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: apremilast
Experimental treatment for acute gout
Drug: apremilast
apremilast 20 mg taken twice daily by mouth
Active Comparator: indomethacin
Medication currently used for the treatment of acute gout
Drug: indomethacin SR
indomethacin SR 75 mg taken twice daily by mouth

Detailed Description:

WITHDRAWN

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must understand and voluntarily sign the informed consent
  • Must have the diagnosis of gout proven by identification of urate crystals from body fluids
  • Must be male age >18 years at the time of consent
  • Must be able to adhere to the study visit schedule and other protocol requirements
  • Must meet the following laboratory criteria:

    • Hemoglobin > 9.0 g/dL
    • White blood cell (WBC) count > 3000/μL and < 14,000/μL
    • Platelet count >100,000/μL
    • Serum creatinine < 2.0mg/dL
    • Total bilirubin < 2.0 mg/dL
    • Aspartate transaminase (AST) and alanine transaminase (ALT) <1.5 X upper limit of normal
  • Males, including those who have had a vasectomy, must agree to use barrier contraception (latex condom) when engaging in sexual activity with a female of child-bearing potential (FCBP) while on study medications and for 84 days after taking the last does of the medication

Exclusion Criteria:

  • Inability to provide voluntary consent
  • Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he were to participate in the study or confounds the ability to interpret the data from the study
  • Females
  • Systemic fungal infection
  • History of recurrent bacterial infection (at least 3 major infections resulting in hospitalization and/or requiring intravenous antibiotic treatment in the past 2 years
  • An active infection at presentation
  • Use of any investigational medication within 4 weeks prior to start of study or 5 pharmacokinetic/pharmacodynamic half-lives, whichever is longer
  • Any use of corticosteroids, cyclosporine, methotrexate, cyclophosphamide, azathioprine, mycophenolate within 4 weeks prior to start of study
  • Any clinically significant abnormality on 12-lead ECG screening
  • Malignancy or history of malignancy (except for treated and cured basal-cell skin carcinomas > 3 years prior to screening)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00997581

Locations
United States, New Hampshire
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
Celgene Corporation
  More Information

No publications provided

Responsible Party: Robert Wortmann, MD, Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier: NCT00997581     History of Changes
Other Study ID Numbers: AP-GOUT-PI-0038
Study First Received: October 9, 2009
Last Updated: July 5, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Dartmouth-Hitchcock Medical Center:
Gout

Additional relevant MeSH terms:
Arthritis, Gouty
Arthritis
Genetic Diseases, Inborn
Gout
Joint Diseases
Metabolic Diseases
Metabolism, Inborn Errors
Musculoskeletal Diseases
Purine-Pyrimidine Metabolism, Inborn Errors
Rheumatic Diseases
Apremilast
Indomethacin
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Cardiovascular Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Gout Suppressants
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Phosphodiesterase Inhibitors
Physiological Effects of Drugs
Reproductive Control Agents
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 27, 2014